21293-29-8
21293-29-8 结构式
基本信息
脱落酸
S-诱抗素
5-(1-羟基-2,6,6-三甲基-4-氧-2-环己-1-烯基-3-甲基-2,4-戊二烯酸
脱落素Ⅱ
休眠酸
脫落酸
ABA,休眠素
脱落酸(ABA)
落叶酸
(+)-脱落酸
(S)-5-(1-羟基-4-氧代-2,6,6-三甲基-2-环己烯-1-基)-3-甲基-(2Z,4E)-戊二烯酸
ABA
ABK
(+)-ABSCISIC ACID
ABSCISIC ACID
ABSCISIC ACID, (+)-
ABSCISIN
(+)-CIS,TRANS-ABSCISIC ACID
DORMIN
[S]-5-[1-HYDROXY-2,6,6-TRIMETHYL-4-OXOCYCLOHEX-2-EN-1-YL]-3-METHYL-[2Z,4E]-PENTADIENOIC ACID
S-(+)-ABA
S-ABA
(S)-(+)-ABSCISIC ACID
(+)-abscisinii
(+)-cis-abscisicacid
(s-(z,e))-methyl
abscisinii
acideabscisique
cis-abscisicacid
dormin(abscissionfactor)
物理化学性质
安全数据
应用领域
常见问题列表
(+)-脱落酸纯品为无色晶体。熔点160~161℃。120℃升华，分配系数为1.8(电中性形式)、0.94(离子形式)。相对密度1.21。在水中的溶解度为3102mg/L(pH 4)。旋光率[a]20D = +409.97R(20℃在乙醇中,10.1mg/mL)。pKa为4.61。溶于氯仿、丙酮、乙酸乙酯和乙醚。微溶于苯和水。紫外最大吸收波长(甲醇)252nm。
大鼠急性经口LD50 >5000mg/kg。大鼠急性经皮LD50>5000mg/kg。大鼠吸入LC50(4h)>5.1mg/L。NOEL:(90d)大鼠每天2000mg/L;(3周)大鼠经皮1000mg/kg; NOAEL1000mg/(kg·d)。
(+)-脱落酸是一种植物生长调节剂，具有诱导植物休眠、抑制种子萌发和植物生长、刺激气孔关闭等多方面的生理作用。
(+)-脱落酸通过如下反应制得：
|
Human Endogenous Metabolite
|
In Arabidopsis cell cultures, Abscisic acid ((S)-(+)-Abscisic acid; 10 μM) simultaneously induces rapid alkalinization of the medium and plasma membrane depolarization.
Abscisic acid (10 μM) increases Ca
2+
in cytosol of Arabidopsis cell suspension. Abscisic acid does not inhibit proton pumping directly but through an increase in cytosolic Ca
2+
.
Lanthionine synthetase C-like 2 (LANCL2) is the natural receptor for Abscisic acid. Abscisic acid, both at the organism levels and in specific muscle cells ex vivo, increases both glucose and fatty acid metabolism in the mitochondria, increases glycogen synthesis, activates PI3K independently of insulin and promotes GLUT4 translocation to the cell membrane.
Abscisic acid (orally; 0.125 µg/kg/day; for 12 weeks) improves glycemic control.
Abscisic acid (orally; 0.125 µg/kg/day; for 12 weeks) results in significantly lower levels of TNF, MCP-1 and IL-6 in the DIO model. Abscisic acid increases metabolic activity in skeletal muscle.
| Animal Model: | Diet-induced obesity (DIO) mice at 4 weeks of age |
| Dosage: | 0.125 µg/kg |
| Administration: | Orally; daily; for 12 weeks |
| Result: | Improved glycemic control in a diet-induced model of obesity |